Get started
Author

Sarah Schlief

Observed names: S. Schlief, S., Schlief, Schlief, Sarah
Institution: Bayer (Germany)
OpenAlex ID: A5073727815
Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity
2024 · Andreas Stahl, Hidehiko Nakanishi, et al. · JAMA Network Open · 30
Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies
2021 · Birgit Geoerger, Bruce Morland, et al. · European Journal of Cancer · 29
PDF
Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system
2009 · Susan Lösler, Sarah Schlief, et al. · Annals of Hematology · 24
Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study
2024 · Andreas Stahl, Noriyuki Azuma, et al. · Eye · 8
PDF
Phase I dose-escalation and pharmacokinetic (PK) study of regorafenib in pediatric patients with recurrent or refractory solid malignancies.
2016 · Birgit Geoerger, Bruce Morland, et al. · Journal of Clinical Oncology · 5
Three-Year Outcomes of Intravitreal Aflibercept versus Laser Therapy for Retinopathy of Prematurity: Interim Analysis of the Efficacy and Safety Outcomes in the FIREFLEYE next Trial
2026 · Andreas Stahl, Hidehiko Nakanishi, et al. · Neonatology · 4
PDF
Correction: Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study
2024 · Andreas Stahl, Noriyuki Azuma, et al. · Eye · 3
PDF
Correlation of efficacy and safety outcomes with regorafenib exposure in patients with hepatocellular carcinoma
2017 · A. Cleton, K. Graudenz, et al. · Journal of Hepatology · 1
SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with diabetic macular oedema
2026 · Clare Bailey, Marion R. Munk, et al. · Eye
PDF
Clinical improvements at Week 36 sustained to Week 64 with aflibercept 8 mg in macular edema following retinal vein occlusion, with significantly fewer injections compared to aflibercept 2 mg: Results from the QUASAR trial
2026 · Khoramnia, Ramin, Hariprasad, Seenu M., et al. · German Medical Science (German Research Foundation)
SPECTRUM: Week 24 data for aflibercept 8 mg indicate improvements in patients with treatment-naïve nAMD and stable outcomes in patients with previously treated nAMD
2026 · Stahl, Andreas, Lange, Clemens, et al. · German Medical Science (German Research Foundation)
Supplementary Material for: Three-year Outcomes of Intravitreal Aflibercept versus Laser Therapy for Retinopathy of Prematurity
2026 · karger, figshare admin, A., Stahl, et al. · Figshare
Plain-language commentary: 2-year findings from the FIREFLEYE next study looking at how well aflibercept injected into affected eyes in babies with retinopathy of prematurity works and how safe it is compared with laser treatment
2025 · Andreas Stahl, Hidehiko Nakanishi, et al. · Therapeutic Advances in Ophthalmology
Time course of treatment-emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment.
2017 · Philippe Merle, Alessandro Granito, et al. · Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)
Compassionate Use Experience with Dasatinib Therapy in Patients after Imatinib and/or Nilotinib Failure.
2007 · Bettina A. Gunawardena, Sarah Schlief, et al. · Blood
Works count: 15
Citation count: 104
H-index: 5
I10-index: 3
Year
Topic
Type